Advertisement
News
Advertisement

Proteonomix (PROT) Updates Status of Clinical Trial

Tue, 02/28/2012 - 3:45am
The Associated Press

(http://www.proteonomix.com)

PROTEONOMIX, INC. (OTCBB: PROT), a biotechnology company focused on

developing therapeutics based upon the use of human cells and their

derivatives, announced today progress regarding human trials on its

product, UMK-121.

Proteonomix has been informed that patient screening has commenced at

the University of

Miami.(http://ctt.marketwire.com/?release856844&id1315555&type1&urlhttp%3a%2f%2fwww.med.miami.edu%2f)

Proteonomix, CTO, Steven Byle stated that "We are excited to see our

years of hard work and research investment coming to fruition. We at

Proteonomix consider ourselves fortunate to be involved in a business

that has the opportunity to try and help people in such dire need. We

look forward to monitoring the trials going forward."

It should be noted that effective March 7, 2012, a new FDA

rule(http://ctt.marketwire.com/?release856844&id1315558&type1&urlhttp%3a%2f%2fwww.fda.gov%2fdefault.htm)

will require that informed consent documents state that the clinical

trial has been or will be registered and the results will be published

in the National Institutes of Health/National Library of Medicine

clinical trials database

(www.clinicaltrials.gov(http://ctt.marketwire.com/?release856844&id1315561&type1&urlhttp%3a%2f%2fwww.clinicaltrials.gov%2f)).

After such date, it is anticipated that any person may find out

additional information and follow the progress of these human trials

on this government informational site.

About Proteonomix, Inc.:

Proteonomix is a biotechnology company focused on developing

therapeutics based upon the use of human cells and their derivatives.

The Proteonomix Family of companies includes Proteoderm, StromaCel,

PRTMI and THOR Biopharma. Proteoderm, Inc. is a wholly owned

subsidiary that has developed an anti-aging line of skin care

products. StromaCel, Inc. develops therapeutic modalities for the

treatment of Cardiovascular Disease (CVD). Proteonomix Regenerative

Translational Medicine Institute, Inc. ("PRTMI") intends to focus on

the translation of promising research in stem cell biology and

cellular therapy to clinical applications of regenerative medicine.

Proteonomix intends to create and dedicate a subsidiary to each of its

technologies. Please also visit

http://www.proteonomix.com/(http://ctt.marketwire.com/?release856844&id1315564&type1&urlhttp%3a%2f%2fwww.proteonomix.com%2f),

http://www.proteoderm.com/(http://ctt.marketwire.com/?release856844&id1315567&type1&urlhttp%3a%2f%2fwww.proteoderm.com%2f),

http://www.otcqb.com/(http://ctt.marketwire.com/?release856844&id1315570&type1&urlhttp%3a%2f%2fwww.otcqb.com%2f)

and

http://www.sec.gov/(http://ctt.marketwire.com/?release856844&id1315573&type1&urlhttp%3a%2f%2fwww.sec.gov%2f).

Forward-looking statements:

Certain statements contained herein are "forward-looking statements"

(as defined in the Private Securities Litigation Reform Act of 1995).

Proteonomix, Inc. cautions that statements made in this press release

constitute forward-looking statements and makes no guarantee of future

performance. Actual results or developments may differ materially from

projections. Forward-looking statements are based on estimates and

opinions of management at the time statements are made.

Add to

Digg(http://digg.com/submit?phase2&urlhttp://www2.marketwire.com/mw/release_html_b1?release_id856844)Bookmark

with

del.icio.us(http://del.icio.us/post?v4&noui&jumpclose&urlhttp://www2.marketwire.com/mw/release_html_b1?release_id856844)Add

to

Newsvine(http://www.newsvine.com/_tools/seed&save?uhttp://www2.marketwire.com/mw/release_html_b1?release_id856844)

Advertisement

Share this Story

X
You may login with either your assigned username or your e-mail address.
The password field is case sensitive.
Loading